SoftOx Solutions AS ("SoftOx") is pleased to announce that the enrolment of
study participants for the clinical investigation «SWIS-02» has been completed.
The study, which has been conducted at Bispebjerg University Hospital is a
confirmatory clinical investigation to document safety and performance of SoftOx
Wound Irrigation Solution ("SWIS") compared to Normal Saline (NS) in a human
wound model. It is a confirmative study and last of two clinical studies on
"SWIS". 

We are very pleased to have completed this enrolment because of the ongoing
lockdown in Denmark, which were affecting our recruitment pace. "With this
pivotal trial we are eagerly looking forward to examining and analyse the study
data and report on the results later in Q2-2021", says Glenn Gundersen, Medical
Director of SoftOx. 

SWIS is under development to become a medical device intended for wound rinsing
and moistening to prevent infections in all types of acute wounds, such as
abrasions, cuts, burns and surgical wounds. 

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS, or
Glenn Gundersen, Medical Director in SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth
Oslo. Our Vison is "Helping the world fighting infections - developing new ways
of eradicating infections and fighting antimicrobial resistance". We are working
to combat major threats to human health, namely the emergence of antimicrobial
resistance (AMR), biofilm infections in chronic wounds and the spread of
viruses. For more information on SoftOx, visit www.soft-ox.com